BPC
NBIX icon

Banque Pictet & Cie’s Neurocrine Biosciences NBIX Stock Holding History

Banque Pictet & Cie’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,501
Closed -$1.65M – 370
2026
Q1 		$1.65M Buy
+12,501
New +$1.66M 0.01% 236
2023
Q2 		– Sell
-8,564
Closed -$867K – 565
2023
Q1 		$867K Sell
8,564
-3,883
-31% -$404K 0.01% 397
2022
Q4 		$1.49M Sell
12,447
-3,555
-22% -$416K 0.02% 337
2022
Q3 		$1.7M Buy
16,002
+720
+5% +$73.1K 0.02% 311
2022
Q2 		$1.49K Sell
15,282
-1,596
-9% -$147K 0.01% 361
2022
Q1 		$1.58M Buy
+16,878
New +$1.43M 0.01% 381

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Banque Pictet & Cie's NBIX Position: Q2 2026 in Review

Banque Pictet & Cie sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 12,501 shares — an estimated $1.65M sold.

Banque Pictet & Cie first reported a position in NBIX in Q1 2022 and held it in 6 quarters. The position peaked at $1.7M in Q3 2022. 427 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Banque Pictet & Cie reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Banque Pictet & Cie sold 12,501 Neurocrine Biosciences shares in Q2 2026, an estimated $1.65M.
  • Banque Pictet & Cie first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 6 quarters.
  • Banque Pictet & Cie's Neurocrine Biosciences position peaked at $1.7M in Q3 2022.
  • 427 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Banque Pictet & Cie's 13F filing for Q2 2026, filed 24 Jul 2026.